GW Pharmaceuticals (NASDAQ: GWPH)topped revenue estimates for the second quarter of 2019, sending the stock climbing over 11% during aftermarket hours on Tuesday. The consensus estimate was for earnings of $1.34 per share on revenue of $47 million.
Total revenue was $72 million compared to $3.3 million in the same period last year.
The company reported a net income of $79.7 million, or $0.21 per share, compared to a net loss of $84 million, or $0.25 per share, in the prior-year quarter.
During the quarter, sales of Epidiolex totaled $68.4 million. Over 12,000 patients have received Epidiolex prescriptions since launch and over 2,500 physicians have generated dispensed prescriptions since launch.
With regards to the European launch of Epidiolex, GW Pharma anticipates approval in early October on positive CHMP opinion. The company expects to launch in France, Germany and the UK by the fourth quarter with launches in Spain and Italy to follow in 2020.
The company is working on the development of Sativex for the treatment of multiple sclerosis spasticity. GW Pharma has already completed over 10 placebo-controlled trials in other conditions.
The company also believes there is potential for CBDV in the fields of autism and epilepsy. The open label study in Rett syndrome and seizures are ongoing.
At June 30, 2019, GW Pharma had cash and cash equivalents of $583.7 million compared to $591.5 million as of December 31, 2018.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on